Does it Matter Whether Canada's Separate Health Technology Assessment Process for Cancer Drugs has an Economic Rationale?
Centre for Excellence in Economic Analysis Research (CLEAR), Li Ka Shing Knowledge Institute, St. Michael's Hospital, Toronto, ON, Canada, jeffrey.hoch@utoronto.ca.
Jeffrey S
JS
Hoch
Jaclyn
J
Beca
Mona
M
Sabharwal
Scott W
SW
Livingstone
Anthony L A
AL
Fields
D000970:Antineoplastic Agents / Q000191:economics / Q000627:therapeutic use*; D002170:Canada; D006801:Humans; D009369:Neoplasms / Q000188:drug therapy* / Q000191:economics; D013673:Technology Assessment, Biomedical / Q000379:methods*
D000970:Antineoplastic Agents